Oral Phenylephrine Phase-Out Puts OTC Brands Under Review

Original Article by Tamar Kahn | Business Day | 21 April 2026

Oral Phenylephrine Phase-Out debate grows as Sahpra weighs evidence, industry warns on access, and pharmacists call for a gradual transition.

Oral Phenylephrine Phase-Out debate grows as Sahpra weighs evidence, industry warns on access, and pharmacists call for a gradual transition.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here